UPSTREAM BIO INC (UPB) Stock Fundamental Analysis

NASDAQ:UPB • US91678A1079

7.68 USD
-0.22 (-2.78%)
At close: Feb 27, 2026
7.69 USD
+0.01 (+0.13%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to UPB. UPB was compared to 520 industry peers in the Biotechnology industry. UPB has a great financial health rating, but its profitability evaluates not so good. UPB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year UPB has reported negative net income.
  • In the past year UPB has reported a negative cash flow from operations.
UPB Yearly Net Income VS EBIT VS OCF VS FCFUPB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -31.38%, UPB is in the better half of the industry, outperforming 65.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -32.43%, UPB is in the better half of the industry, outperforming 73.65% of the companies in the same industry.
Industry RankSector Rank
ROA -31.38%
ROE -32.43%
ROIC N/A
ROA(3y)-59.22%
ROA(5y)N/A
ROE(3y)-136.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UPB Yearly ROA, ROE, ROICUPB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for UPB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UPB Yearly Profit, Operating, Gross MarginsUPB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • UPB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for UPB has been increased compared to 1 year ago.
  • UPB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UPB Yearly Shares OutstandingUPB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
UPB Yearly Total Debt VS Total AssetsUPB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • UPB has an Altman-Z score of 18.68. This indicates that UPB is financially healthy and has little risk of bankruptcy at the moment.
  • UPB has a Altman-Z score of 18.68. This is amongst the best in the industry. UPB outperforms 88.65% of its industry peers.
  • There is no outstanding debt for UPB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.68
ROIC/WACCN/A
WACC8.61%
UPB Yearly LT Debt VS Equity VS FCFUPB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • UPB has a Current Ratio of 32.67. This indicates that UPB is financially healthy and has no problem in meeting its short term obligations.
  • UPB's Current ratio of 32.67 is amongst the best of the industry. UPB outperforms 98.27% of its industry peers.
  • UPB has a Quick Ratio of 32.67. This indicates that UPB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 32.67, UPB belongs to the top of the industry, outperforming 98.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 32.67
Quick Ratio 32.67
UPB Yearly Current Assets VS Current LiabilitesUPB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • UPB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -99.70%.
  • Looking at the last year, UPB shows a decrease in Revenue. The Revenue has decreased by -0.42% in the last year.
EPS 1Y (TTM)-99.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.95%
Revenue 1Y (TTM)-0.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.52%

3.2 Future

  • UPB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.80% yearly.
  • The Revenue is expected to grow by 40.13% on average over the next years. This is a very strong growth
EPS Next Y67.9%
EPS Next 2Y26.81%
EPS Next 3Y15.68%
EPS Next 5Y8.8%
Revenue Next Year25.46%
Revenue Next 2Y-16.6%
Revenue Next 3Y-9.71%
Revenue Next 5Y40.13%

3.3 Evolution

UPB Yearly Revenue VS EstimatesUPB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
UPB Yearly EPS VS EstimatesUPB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • UPB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UPB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UPB Price Earnings VS Forward Price EarningsUPB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UPB Per share dataUPB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as UPB's earnings are expected to grow with 15.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.81%
EPS Next 3Y15.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for UPB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UPSTREAM BIO INC

NASDAQ:UPB (2/27/2026, 8:00:02 PM)

After market: 7.69 +0.01 (+0.13%)

7.68

-0.22 (-2.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-18
Inst Owners76.89%
Inst Owner Change11.93%
Ins Owners0.05%
Ins Owner Change2.73%
Market Cap415.03M
Revenue(TTM)2.80M
Net Income(TTM)-122.77M
Analysts81.67
Price Target49.47 (544.14%)
Short Float %7.92%
Short Ratio3.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.31%
Min EPS beat(2)-19.62%
Max EPS beat(2)20.24%
EPS beat(4)1
Avg EPS beat(4)-46.15%
Min EPS beat(4)-181.12%
Max EPS beat(4)20.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)98.52%
Min Revenue beat(2)4.84%
Max Revenue beat(2)192.2%
Revenue beat(4)4
Avg Revenue beat(4)81.45%
Min Revenue beat(4)4.84%
Max Revenue beat(4)192.2%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.49%
EPS NQ rev (1m)-2.54%
EPS NQ rev (3m)3.95%
EPS NY rev (1m)-0.69%
EPS NY rev (3m)8.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.68%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)13.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 148.28
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.1
EV/EBITDA N/A
EPS(TTM)-3.47
EYN/A
EPS(NY)-3.18
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.26
OCFYN/A
SpS0.05
BVpS7.01
TBVpS7.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.38%
ROE -32.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.22%
ROA(5y)N/A
ROE(3y)-136.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.44%
Cap/Sales 10.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.67
Quick Ratio 32.67
Altman-Z 18.68
F-Score3
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)661.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)11.46%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-99.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.95%
EPS Next Y67.9%
EPS Next 2Y26.81%
EPS Next 3Y15.68%
EPS Next 5Y8.8%
Revenue 1Y (TTM)-0.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.52%
Revenue Next Year25.46%
Revenue Next 2Y-16.6%
Revenue Next 3Y-9.71%
Revenue Next 5Y40.13%
EBIT growth 1Y-93.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-95.03%
EBIT Next 3Y-36.38%
EBIT Next 5YN/A
FCF growth 1Y-56.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.02%
OCF growth 3YN/A
OCF growth 5YN/A

UPSTREAM BIO INC / UPB FAQ

What is the fundamental rating for UPB stock?

ChartMill assigns a fundamental rating of 3 / 10 to UPB.


What is the valuation status for UPB stock?

ChartMill assigns a valuation rating of 0 / 10 to UPSTREAM BIO INC (UPB). This can be considered as Overvalued.


Can you provide the profitability details for UPSTREAM BIO INC?

UPSTREAM BIO INC (UPB) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for UPB stock?

The Earnings per Share (EPS) of UPSTREAM BIO INC (UPB) is expected to grow by 67.9% in the next year.